Chemical Information
Antiviral agent ID	DrugRepV_0232
Antiviral agent name	JB1a
Structural Information
2-D Structure is not available	3-D Structure is not available
Clinical Information
Biological Information
Secondary Indication	Ebola virus (EBOV) NA ME718-1976/Yambuku-Ecran
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Potential drug target)	Virus entry
Secondary Indication (Model system) [cell lines/ animal models]	VeroE6
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	500/well TCID50
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Pre infection
Secondary Indication (Drug concentration)	2 μg/mL
Secondary Indication (Cell based assay)	Real-time PCR
Secondary Indication (Change)	Increase
Secondary Indication (Type of Inhibition)	Difference in Ct values of untreated vs treated [ ?5.48 ± 0.50 Ct ]
Reference	Dowall SD, Bewley K, Watson RJ, Vasan SS, Ghosh C, Konai MM, Gausdal G, Lorens JB, Long J, Barclay W.Antiviral Screening of Multiple Compounds against Ebola Virus..Viruses. 2016 Oct 27;8(11). pii: E277. PMID:27801778
Comment	Nine compounds caused no reduction in viral replication despite cells remaining healthy, so they were excluded from further analysis (zidovudine; didanosine; stavudine; abacavir sulphate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine). A second screen of the remaining compounds and the feasibility of appropriateness for in vivo testing removed six further compounds (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and Tasigna). The three most promising compounds (17-DMAG; BGB324; and NCK-8) were further screened for in vivo activity in the guinea pig model of EBOV disease. Two of the compounds, BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concentrations tested, which warrants further investigation.